Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 4/20 | 0.48 |
| ▸ | CDK1 | P06493 | 4/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 10/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478495 | 0.86 | CCNB2 (0.53) | CCNB2CDK1CCNB1CCNB3MKNK1 | |
| SCHEMBL13638594 | 0.81 | MAPK8 (0.61) | CCNB2CDK1CCNB1CCNB3MKNK1 | |
| SCHEMBL28857024 | 0.81 | CCNB2 (0.67) | CCNB2CDK1CCNB1CCNB3MKNK1 | |
| SCHEMBL13638678 | 0.80 | IKBKB (0.42) | CDK1CCNB1EGFRHDAC1CDK4 | |
| SCHEMBL13638547 | 0.79 | RET (0.63) | CCNB2CDK1CCNB1CCNB3MKNK2 | |
| SCHEMBL14193549 | 0.78 | CDK1 (0.76) | CCNB2CDK1CCNB1CCNB3MKNK1 | |
| SCHEMBL13638546 | 0.77 | RET (0.46) | CCNB2CDK1CCNB1CCNB3MKNK1 | |
| SCHEMBL13638549 | 0.77 | RET (0.46) | CCNB2CDK1CCNB1CCNB3MKNK2 | |
| SCHEMBL14612854 | 0.77 | IKBKB (0.42) | CDK1CCNB1CDK4CDK2 | |
| SCHEMBL13638548 | 0.76 | GSK3B (0.48) | CCNB2CDK1CCNB1CCNB3MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | CCNB2 1081/4885CDK1 555/4885CCNB1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.